Actualités

European equities traded in the US as American depositary receipts were edging lower late Wednesday

NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.

A new market could accelerate Lilly's oral obesity ambitions

European equities traded in the US as American depositary receipts were tracking higher late Tuesday

The U.K. becomes Lilly's first international market for the pill.

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns […]

Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI...

The MHRA is the first European regulator to give Foundayo a regulatory blessing, with the drug still under review by the EU.

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of […]

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets. Yet another competitive advantage for investors to […]

NEW YORK, Aug 10 (Reuters) - Hims & Hers Health on Monday posted second-quarter revenue above estimates and raised its annual revenue forecast, as the telehealth company benefited from an increase in

The European stock markets closed mixed in Monday trading as investors continue to gauge development

Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

While a disappointing late-stage readout sent biotech stocks tumbling, all hope may not be lost for the emerging approach to treating cardiovascular events.

(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second parag

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now.

Amazon.com Inc.‘s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced on Thursday that the service would automate eligibility checks, prior authorizations, and billing,...

Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doust

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?

Dismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.

Berobenatide is one of the keys to Pfizer's future.

Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.

A Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.

<body><p>STORY: From BP making huge profits to Toyota's raised forecast... This is the Week in Numbers.&nbsp;</p><p>:: Week in Numbers&nbsp;</p><p>:: $5.73 billion</p><p>$5.73 billion was how high BP's second-quarter profit reached.</p><p>The British energy major cited higher energy prices, trading and refining margins.</p><p>Oil giants have scored big this year from market volatility caused by the U.S.-Iran war.</p><p>BP rival Shell also reported a doubling of second-quarter profit a week before.</p><p>:: 12%</p><p>About 12% was how much SpaceX shares dropped by after its first-ever earnings call as a public company.</p><p>Investors were worried about heavy AI spending on data centers and Nvidia chips.</p><p>Quarterly capital spending on AI reached $15.8 billion.</p><p>Elon Musk's rocket company said the economics of the investments were improving, but suggested AI investments would stay elevated.</p><p>:: $497 million</p><p>$497 million was the sales figure for Novo Nordisk's Wegovy pill.</p><p>That disappointed investors as it just missed expectations.</p><p>Shares dropped despite the Danish drugmaker raising its full-year profit and sales outlook.</p><p>Novo is battling to regain ground from U.S. rival Eli Lilly in the obesity drug market.</p><p>:: 10%</p><p>More than 10% is how far Lufthansa shares fell during the week.</p><p>Investors sold off after the German airline cut its profit outlook.</p><p>It further warned earnings could fall this year after the Iran war drove up fuel costs.</p><p>The warning showed the pressure European airlines face due to higher jet fuel costs.</p><p>:: $6.3 billion</p><p>$6.3 billion was the size of the share buyback announced by Toyota.</p><p>The world's biggest automaker also raised its annual operating profit forecast by 13%.</p><p>But Toyota also reported a 9% slide in first-quarter profit - its fifth straight quarter of declines.</p><p>It was hit by falling sales in China while the Iran war also raised costs for raw materials and parts.</p></body>

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...

Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet